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Abstract
It would seem that differentiation of stem cells is the remedy of modern times.Yet stem cell research is more complex
that the public may recognize and is still in the developmental stage. Recent breakthroughs show promise; various
guidelines provide structure to this growing field but it is not ready for gross public application. The objective of this
paper is to research various different methods of stem cell production and application. Methods included reviewing
articles and studies to evaluate the process in production of affective stem cells.There are many therapies that illustrate
this research. Upon completing and explaining this phase, further analysis of research presented risk factors such as
negative immune responses, tumor, and teratoma formation are discussed. This paper further examines the different
complications that may be triggered by stem cell therapy. The danger analysis is briefed to describe the risks involved
in stem cell therapy while explaining the ongoing research and discoveries to assist in limiting these risks. This paper
culminated with the success of the most affective form of therapy to date.There are ongoing studies directed to limiting
stem cell therapy for safe and risk-free application. Nevertheless, no definite conclusion can be reached as to how stem
cells can be limited to the point of remaining simultaneously pluripotent and effective.
Introduction
A young woman walks into her doctor’s office complaining of
what seems to be a pimple that does not go away. She initially
treated it with over counter creams, then a facial and many dermatologist visits. Upon a more extensive examination the specialist realized that this was not the average case of adolescent
acne and ordered blood work. The test revealed that this girl
has type-one diabetes. Her plans to go to college were placed
on hold and her life completely changed. What if diabetes didn’t
have to be a life altering disease? What if glucose monitoring
and insulin injections were replaced with a one-time stem cell
therapy that could replace the damaged cells? This example did
occur and the girl is being treated with subcutaneous insulin
infusion therapy. Stem Cell Research has not reached this breakthrough but the hope is that in the future stem cells will be used
to test medical treatments and replace cells lost by devastating
diseases that currently have no sustainable cure.
The first several divisions of the mammalian fertilized oocyte
give rise to totipotent cells. These cells can form cells in the
placenta, embryotic sack, and any cell in the body. Once cells are
designated for the body they are termed pluripotent cells.These
embryotic stem cells have virtually limitless potential and are an
invaluable resource for the biomedical community. Along with
the importance of these cells arises a responsibility of using
them correctly. The process of understanding how these stem
cells work and the services they can provide has not been an
easy feat. This battle has been fought in both the courtrooms
and laboratories. The legal system bears the responsibility of
creating a system in which guidelines are being followed and
ethics upheld. This is an ongoing battle, and there is no undermining this work. Regardless of several ongoing debates and
some legal verdicts, the biomedical community is addressing
stem cell research, cell regeneration, and organ construction
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from two different perspectives. There is ongoing promising
research being done on organ and cell regeneration with the
use of somatic stem cells. Specific mature, undifferentiated, adult
cells are reprogramed to function as stem cells and referred to
as induced pluripotent stem cells (iPSC). These cells, generally
found in the epithelial cells of an adult organ, have already been
assigned a task and are therefore limited to the regeneration of
that particular cell or organ. However, being that they are extracted from the patient, it is assumed, although not tested, that
these cells will face less rejection after implantation because
of the body’s familiarity with the cells. An alternative form of
adult stem cells is activation of somatic stem cells (Stem Cell
Information, n.d.) within the body. These cells reside within a
healthy body and function as a natural maintenance system by
regenerating aged or damaged tissue and replacing lost cells.
Examples of the somatic stem cells are cord blood and bone
marrow. The third of these general stem cell approaches allows
for more potential but at a greater risk; pluripotent embryotic
stem cells (ESC) can be used to create any cell or organ but at
a higher probability for tumor growth.There are several distinct
differences between embryotic and adult stem cells. Adult stem
cells are rare cells that require extraction, isolation, and then in
vivo cell culturing, to multiply. This cell culture process has not
fully developed and is a great deal more complicated than the
growth of ESCs (Herberts et. al. 2011., Shanthly et. al. 2006).
This paper will explore the potential of regenerating tissue by
means of pluripotent stem cells, as well as discuss literature on
growth of these cells to build tissues and replace cells. Upon exploring the processes of in vitro and in vivo differentiation, in
both induced pluripotent stem cells (iPSC) and human embryonic
stem cells (hESC), one can question the technology needed to
operate these cells. Is it possible to limit stem cells to differentiate, as they would in utero, to create a select tissue or organ?
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Methods
This document was amassed by referencing original research and
peer reviewed scholarly articles. US government websites and
portions of scholarly articles were accessed to gain knowledge
about the background, history, and general methods involved in
stem cells therapies. Specific topic information, regarding the research question, was collected, reviewed, and analyzed. Google
Scholar, and databases that are made accessible through the
Touro College online library, such as Proquest and Ebsco, were
used to search and access documents related to the research
topic.The following are examples of key words were used: stem
cell and apoptosis, c-myc, tumorigenic factors, in vivo growth,
nodal signaling. There was no discrimination made regarding the
date of publication on articles.

History
Initial stem cell research dates back to 1870, with in vitro fertilization of an oocyte. Any form of promising finding were slow
until research intensively propelled in the late nineteen seventies. Notable accomplishments include cloning of mammals in
1997 and development of the first stem cell culture in 1998.
The virtually simultaneous discovery of cloning and stem cells
were the building block of forthcoming research. Stem cells cultured in today’s laboratories are removed from the blastocyst
early in differentiation and frozen in their state until they are
differentiated into the cells required for a specific medical therapy (Shanthly et. al. 2006). Research is ongoing and promising;
the biomedical community has only scratched the surface of
the untapped potential of stem cells. There are various issues
and setbacks that are limiting stem cell potential (Stem Cell
Information, n.d.).
Stem cell research raised sharp scientific, technological, ethical, and political controversies. The United States federal and
state governments enforced laws to enhance and restrict actual
stem cell research. States such as Florida and New York agree
to provide state funding while other states such as Arkansas
and Michigan have placed bans on the creation and use of ESC
for biotech research (Vestal 2008). Some forms of stem cell
research and experimentation are more disputed than others;
stem cells derived from oocytes are more controversial than
induced adult cells. For example, in 2006 the Senate passed a
law allowing federal money to benefit the specific research of
iPSC, umbilical blood and bone marrow treatments but not
ESC. However, in 2011 President Obama removed all bans that
restricted federal funding from being assigned to new lines of
embryotic stem cells. Regardless of the origin of the cell, human
stem cells research raises ethical sensitivities. The ethical policies are continuously evolving and the biomedical community is
attempting to overcome the challenges to ensure that research
is carried out in an appropriate manner (Levin et. al. 2013).

In addition to legal constraints the anatomical components that
comprise stem cells are intrinsically a hindrance. The same factors, enzymes, and transcription that insure the cell’s ability for
self-renewal cause biomedical complications (Li et. al. 2015).

Differentiations
Some mammalian tissues, such as the skin and liver, have the
ability to regenerate yet others cannot. The capability of bioengineering and sustaining all organs, regardless of their regeneration factor, will be invaluable; this can ultimately circumvent the
transplant system ensuring that patients don’t die waiting for an
organ. Regeneration capability is reliant on stem cells. For the
purpose of this paper stem cells are divided into two categories, embryonic stem cells (ESC) and induced pluripotent stem
cells (iPSC). In more recent years, researchers have developed
methods of directly reprograming differentiated cells to produce iPSC. iPSCs are rare and found in only some differentiated
tissues throughout the human body. A common use for iPSC
is bone marrow transplants to fight leukemia. Although only
one in every one hundred thousand cells is stem cell, advanced
techniques allow for harvesting and collecting those cells in
concentration to be donated by injecting the donor with colony-stimulating factor 3 (CSF 3). This glycoprotein stimulated the
bone marrow to produce more stem cells; a necessary tool to
collecting these otherwise dispersed cells. Such techniques can
be used to collect adult stem cells but the process is tedious and
does not allow for the unlimited potential hESC offer (Shanthly
et. al. 2006). Although iPSC involves complications, such as the
complexity of collection, it also provides therapeutic potential
because these cells are harvested from a patient’s own cells.This
can alleviate tissue and cell rejection complications.
Since adult stem cells cannot give rise to all cells and tissues
in the body, the ideal regenerative cell is embryotic stem cell.
There are three different forms of embryonic stem cells used
for medical research. The foremost method, true embryotic
stem cells, is made from fertilized eggs generally donated by
patients undergoing in vitro fertilization. Somatic cell nuclear
transfer (ntES cell) is the process of creating an embryotic cell
by inserting the nucleus of a general human cell into an egg cell.
Although this technology has not been tested on higher mammals, it can be of great use because the nucleus of the cell will be
a genetic match to the patient. The third form of ESC, not ready
for clinical use, is called parthenogenetic embryonic stem cells
(pESC). Through the process of parthenogenesis, an unfertilized
egg is stimulated into differentiating as an embryotic cell would
(Shanthly et. al. 2006).

Stem Cell Links to Tumorigenic Cells
Regardless of the types of ESC, these stem cells are derived from
the core of mammalian blastocysts and can multiply infinitely
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and differentiate into three germ layers: mesoderm, endoderm
and ectoderm. However, there are stem cells that have been
documented to have significantly more genetic mutations as
they grow in vitro. Research performed on zebra fish indicates
that nodal signaling and pathways are found in both metastasized
cancerous cells and embryotic stem cells yet not in healthy skin
cells (Topczewska et. al. 2006). Nodal proteins are growth factors important to pattern formations needed for the embryotic
differentiation, specifically as it relates to the formation of the
mesoderm and endoderm .(Shen 2007). Activation of the nodal
pathways is tightly regulated and prompts self-gene inscription
with positive and negative feedbacks .(Cheng, Sun, 2014). The
similarities between ESC and tumorigenic cells may lead to discoveries that can limit the association between stem cells and
cancer. Nodal signaling pathways are not the only unique link
between stem cells and metastasized tumor cell; telomerase is
an enzyme that facilitates growth and development of DNA in
ESC but also found in upwards of fifteen times more often in
cancer cells than in healthy cells .(Hiyama, Hiyama, 2007).
Nonsense-mediated mRNA decay (NMD) is been known to
clean RNA in order to protect from early termination. At the
PTC site, the location where early termination would commence, the NMD complex is assembled. This complex balances
and regulates the proteins and is essential for homeostasis and
overall survival of not only the embryonic cell, but organisms as
a whole. One factor of the NMD complex is Smg5, this factor
is involved in telomere and telomerase maintenance. Thus this
NMD factor and Telomerase protein are both essential components that regulate cell viability. They may cause cell fatality or
paradoxically, cancer (Li et. al. 2015).
Understanding the similarities between these cells help with
limiting ESC. This process is called clinical transitions; scientific
knowledge is gathered, understood and then turned into medical treatments. Regardless of these setbacks, the utility of these
cells should not be undermined; simple laboratory practices
such as freezing can assist with excess cell growth. Chemicals
have been tested to determine if ESC can be treated to induce
certain forms of apoptosis. Apoptosis is the shrinking of a complete cell and its membrane. Apoptosis differs from the generic
form of cell death by the fact that it does not leave residue.
Excess cell components that did not shrivel; undergo phagocytosis. The purpose of these chemicals would be to generate
cell death and on the specific component of the cell that may
lead to complications, while leaving the remainder of the stem
cell unharmed. Research performed on these compounds and
chemical were published in 2012 and these findings claim to
identify compounds that altered the viability of ESC (Conesa
et. al. 2012).

38

Research In Vivo/ In Vitro
A ten-year research program beginning in the late 1980’s studied
soft tissue engineering using totipotent stem cells. The experiment used mouse embryotic stem cells to attempt to build lymphatic tissue, among other structures. Prior to commencement
the researchers set out to establish what would be an ideal
environment for embryogenesis. Building tissues in vivo requires
an environment that mimics all aspects of uterus or in vitro development; components such as nutrient and culture conditions
are key. However, the physical creation of such an environment
is quixotic, at best (Chen et. al. 1997, Shanthly et. al. 2006). A
later study characterizes the complexity of stem cells by explaining the conditions for maintaining undifferentiated status.
This study dictates that FGF2 and conditioned medium (CM)
support hESC in an undifferentiated state. In 2005 undifferentiated hESC were maintained with either FGF2 or CM. These
stem cells remained in undifferentiated colonies apposed to the
hESC that were maintained without these factors. Maintenance
of the undifferentiated cells is an extremely delicate process,
indicating that the steps from that point forward, toward proper
differentiation, is that much more complex (Sumi et. al. 2007,
Umar et. Al. 2014).
Development of any tissue, regardless of its origin requires
three steps: cell differentiation, complex tissue formation, and
the building of a three-dimensional, three-layered germ celled
organ (Chen et. al. 1997). The most complex portion of complete in vitro embryogenesis is the maintenance of a live culture
throughout this process. As it is with a fetus, tissues, and organs
can only function if the fetus is alive. Considerable research has
been completed, and is ongoing, on many different forms of tissue growth.To better understand the processes of building cells
and tissues with stem cells, this paper will only be discussing
two different tissues developed in culture, cardiac myocytes and
lymphoid tissues. The decision to use these specific examples is
based on varied dates of the research and the difference in tissue complexity, due both to function and development of each
cell.

Cardiac Myocytes
The differentiation of stem cells to cardiac myocytes is a rather complex. Cardiac muscle is a prime example of a complex
tissue due to the various forms of specific muscular tissues
and their functions as it relates to an efficiently operating
heart. Cardiac tissue is made up of interlocking, single nuclei,
striated, muscle fibers. The unique and complex aspect of this
tissue includes the intercalated disc, which assist in conduction
speed, and autorythmicity, the ability to set its own contractions. Research published in April of 2011 suggests promising
potential of differentiation of cardiac myocytes from hESC. By
inhibiting Bone Morphogenic Proteins (BMP), a growth factor,
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during cardiac differentiation, cardiogenesis is initiated. This
step is far from the only one that is needed to allow for ESC
to be transplanted for therapeutic uses. Additional research
is required such as the study of the regulation of retinoid sig-

Table 1
ESC:

iPSC:

SSC:

Derived from inner
mass of blastocyst

Derived from somatic
cells

Isolated from postnatal
adult tissue

Allogenic material

Autologous or Allogen- Autologous or
ic material
Allogenic material

Pluripotent

Pluripotent

Multipotent

Can differentiate into Can differentiate into
all three germ cells
all three germ cells

Can differentiate to
limited cell types.

Self-renewal

Self-renewal

Limited Self-renewal

Indefinite Growth
Significant Teratoma
Risk

Indefinite Growth
Significant Teratoma
Risk

Limited Lifespan
No Teratoma Risk

Serious Ethical Issues Serious Ethical Issues

Serious Ethical Issues

Immuno-priviliged

Unpredictable

Not Immuno-priviliged

(Prendergast 1999)
naling, the key that defines the difference between ventricular
and arterial myocytes (Zhang et. al. 2011, Hartman et. al. 2014).

Lymphatic Tissue
The microenvironment needed for embryogenesis is delicate.
Being that lymphoid cells develop toward the end of this process, it was difficult to assume that the microenvironment need
for ES cultures could be sustained until that point. Initiation of
the research began with mice. Through the use of viral vectors,
oncogenes were inserted and developed in vivo to produce B
and T cells. Many attempts and adjustment were made.The generation of B and T cells from lymphatic tissue was rare at the
time publication of this journal but at the end of the research it
was confirmed that lymphoid precursor cells could be derived
from ESC. These years of research, experiments, and analysis of
data only begins to explain the complexity of building tissues,
regardless of their origin (Chen et. al. 1997).

Complications
Regardless of the difficulty of building tissues from stem cells
and the improvements to cell cultures explained in cardiomyocytes formation, there are other complications that require
attention. In fact, some stem cell therapies such as bone marrow
transplants with somatic stem cell, do not involve the intricate
complexities that tissue growth requires. Yet even these therapies must be addressed as it relates to the other risk factors
involved in such a therapy. Risk factors begin in procurement
and linger through the many phases involved, beginning with culturing and injection. Subsequent to any initial success, long-term
affects must be analyzed. There is deficient clinical experience

in embryonic and adult stem cells. This lack of experience is an
inevitable aspect of relatively new, current, and ongoing research
and results in a variety of complications, after stem cell injection
(Herberts et. al. 2011).
General observations of the three most common forms of stem
cells are summarized in Table 1. Improved comprehension of
the differences and characteristics of these cells will assist in
establishing their risk analysis.
An example of a consequence is tumor formation. This is a
known complication that is being investigated from different
standpoints. Understanding cell growth and death is crucial to
such an analysis.The Myc gene family encompassed both factors.
It is for that reason that this paper uses c-Myc as an example
of a protein that may help limit tumor genesis. In addition fifty
percent of tumor formation found in mouse research of iPSC is
attributed to c-Myc.

Tumor Formation
The basic and universal self-renewal factors that assist in
feedback and feed forward loops is Oct4, Sox2 and Noanog.
However, the Myc gene family is additional self-renewal proteins
and factors that affect intrinsic stem cell existence and apoptosis.
Research published in 2007 investigated the function of c-Myc in
stem cells regulation, differentiation, and apoptosis. Initially the
tests were performed on mouse stem cells and later applied to
hESC. It was widely known that that c-Myc is required to regulate normal cell development. However, the application of this
factor in hESC regulation was confirmed and verified as being
expressed as three different factors of the same family (Myc,
Mycn, MycL1). Each of these Myc proteins were tested and found
in the mRNA of hESC. Furthermore, just as c-Myc was present in
regulation of mice cells, it was traced in undifferentiated human
stem cells. Testing of this protein suggests that c-Myc is a factor
of self-renewal.This research further investigated if c-Myc would
also affect apoptosis and differentiation (Sumi et. al. 2007).
The properties of the c-Myc protein are best explained when
looking at cancer cells. The protein factor c-Myc is found to be
uncontrolled in end-stage cancers. This overexpression in tumorigenic cells helps explain the role it plays in normal cell growth,
stem cell proliferation, differentiation, and apoptosis. Even prior
to a complete discovery of the potential of c-Myc, it was known
that increased levels of c-MYC indicated the initiation of cell
death.There are various pathways in which apoptosis is initiated.
The first is by the regulator p53 ultimately activating BAX. The
second is activation of PI3’K-AKT.The third and final pathway to
cell apoptosis is through cell ligations that activate c-Myc. The
activation and increase of this protein then caused apoptosis
(Prendergast 1999).
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Being that this factor plays a role both in the differentiation of
stem cells and the death of tumor cells, it must be assumed
that investigations on regulation of this protein may be vital to
advancements in stem cell therapy. With better control of this
protein a clinical laboratory scientist may be able to use it in
either furthering the differentiation of cells or leaving them in an
undifferentiated state when deemed necessary.The link between
the Myc gene family and oncogenic cells will additionally assist
with the considerable complications facing stem cell therapy,
tumorgenesis.
Aside for the risk of essentially causing tumor formation, stem
cell therapy may also affect the growth and formation of existing
tumor cells. If, for example, a patient has a dormant tumor of
cancerous cells, stem cell therapy may active it. This has not
been proven but is under investigation with the use of mouse
stem cells.

Immune Response
Any donation requires proper human leukocyte antigen matching (HLA); stem cell therapy is no different.Taking care to ensure
that the donor and recipient match decreases the risks of Graft
Verse Host Disease (GVHD). As detailed in table one, some
forms of stem cell therapy are allogeneic.Therapies that are not
recognized by the body risk immune rejection. Even those that
are immune privileged (hESC) may be subject to rejection and/
or an inflammatory response due to the increase in response
stimulus, caused by the actual stem cell therapy induction. For
that reason, stem cell therapy may be administered while the
patient is on immune suppressants. Placing a patient on immune
suppressants runs the risk of adverse drug reactions. There are
ongoing studies investigating different methods of stem cells
growth in vivo that will limit the risk of rejections and GVHD.
Such studies include introduction of mesenchymal stem cells
in vivo. Data from such research indicated that these stem
cells tranquilize the immune system and regulate its responses
(Herberts et. al. 2011).

Teratoma
A teratoma is a benign mass composed of a hazardous mixture of tissues, generally resembling remnants of all three germ
layers. It is established in vivo and assumed to be congenital.
Being that pluripotent stem cells can create all three layers,
this therapy is susceptible to such a risk. In fact the same characteristics that defines stem cell, pluripotency, are the same
trait that creates teratomas. Research produced in 2011
details the comparative affects of tumor formation on both
hESC and iPSC. The research indicates that because iPSC is a
stem cell engineered in vitro and thus a more controlled cell
than hESC, iPSC is less susceptible to tumor genesis. In fact
the reason that teratomas are found less frequently in iPSC is
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because the heterogeneity of this cell causes slower growth
rate (Zhang et. al. 2012).
In addition to cell type effects on teratomas, injection sites may
also influence distinctive increase or decrease levels of formation. Although not enough clinical research and analysis can confidently support this claim, it is reasonable (Zhang et. al. 2012).
More research has been performed on mouse stem cells to
detect the correlation of the environment in which the stem
cells are injected into and malignant tumors. Although tumor
growth differs from teratomas, these discoveries may lead to
additional exploration into the plausible affect of increased teratomas based off of site administration (Herberts et. al. 2011).

Success
Success is a complicated term to define when associating
it with ongoing scientific research. Success can be attributed
to a research breakthrough or a clinical accomplishment; it’s
simply relative. Longevity is fundamental determinate of success. Pluripotent haematopoietic stem-cell transplantation for
cancer therapy has made significant stride since initial investigations over sixty years ago. It progressed from research that
was plagued with complications and hurdles to a standard form
of treatment. This blood forming stem cell is the only therapy
approved for standard use because of sufficient understanding of the cells, possible complications, and long term affects.
Expansion of this therapy for use other than replacement of
blood and immune cells causes similar complications mentioned
throughout this document. There are many trials taking place
and success may be recognized within each trial but a complete
understanding of overcoming challenges and complications can
only be determined by continual research and the test of time
(Stem Cell Information, n.d.).

Conclusion
Research, along with case studies and accounts show there are
far more complications with stem cells than would appear at
first glance; they require numerous forms of adjustments to
insure an innocuous treatment. Limiting stem cell therapies is
a promising prospect, and in some therapies it has been successful. However, there is insufficient research completed at this
time to form a definite universal response for limiting any form
of stem cell for every therapy application.
Researchers are investigating the factors that cause the risks
involved in various therapies and consequently exploring remedies and suggestive solutions. However, stem cell therapies
involve a multitude of complexities, some yet to be ascertained.
The reason for these uncertainties appears to be based on the
varied potential administrations, forms of stem cells (hESC, iPSC,
ntES), their associated risks, and the limitless therapies they can

Stem Cells Differentiation into a Specific Organ

produce. This research is a relatively new and revolutionary
field of study. With increase research, funding, and integration
of continual findings, selectively listed in this paper, scientists
are advancing to the goal of utilizing all that stem cells have
to offer. This includes the capability to understand its potential,
related limitations, and safely developing the two in an effort to
advance medicine. Stem cell therapy is the promise for infinite
preventative care and treatment options.
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